NVCR News and Press, NovoCure Limited From 10/28/21

Shares of NovoCure (NASDAQ: NVCR) were sinking 15.5% this week as of the market close on Thursday, according to data from S&P Global Market Intelligence . The decline stemmed primarily from the company's disappointing third-quarter update. NovoCure reported net reve...

The following slide deck was published by NovoCure Limited in conjunction with their 2021 Q3 earnings call. For further details see: NovoCure Limited 2021 Q3 - Results - Earnings Call Presentation

NovoCure Limited (NVCR) Q3 2021 Results Conference Call October 28, 2021 08:00 AM ET Company Participants Ingrid Goldberg - VP, Finance and IR Bill Doyle - Executive Chairman Asaf Danziger - CEO Ashley Cordova - CFO Pritesh Shah - Chief Commercial Officer Conference Call Participants Cory Kas...

NovoCure (NVCR -6.6%) shares are trading sharply lower in the morning hours after the company lagged expectations with its Q3 2021 financials and forecasted a prolonged timeline for a final data readout from a pivotal study. The maker of Optune Tumor Treating Fields delivery sy...

Novocure (NASDAQ:NVCR) announces that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields ((TTFields)) together with paclitaxel for treatment of patients with platinum-resistant ovarian cancer. Following the completion of en...

Quarterly net revenues of $133.6 million with 77% gross margin Last patient enrolled in phase 3 pivotal INNOVATE-3 trial for recurrent ovarian cancer Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2021, highlighting comme...

Final data from INNOVATE-3 trial anticipated in 2023 Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with paclitaxel for treatment of pat...

Highlights include presentations by external authors studying the effects of concurrent Tumor Treating Fields and chemoradiation for patients with newly diagnosed glioblastoma Novocure (NASDAQ: NVCR) today announced 15 presentations on Tumor Treating Fields (TTFields) will b...

The stock market loves instant gratification. When forced to wait for a potentially good thing to pay off, some traders can begin to lose interest. Cancer treatment company Novocure (NASDAQ: NVCR) , which uses low-power electrical fields to disrupt the growth of cancer cells , i...

Aggressive forms of cancer can be devastating to patients and their families. This kind of diagnosis brings uncertainties about the quality of life and the length of time a patient has left. Healthcare company Novocure (NASDAQ: NVCR) aims to improve both these aspects for patien...